Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

ISIS Pharmaceuticals, Inc. : Webcast Alert: Isis Pharmaceuticals' First Quarter 2013 Financial Results Conference Call

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/02/2013 | 07:00pm CEST

CARLSBAD, Calif., May 2, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:

    What:   Isis Pharmaceuticals' First Quarter 2013
            Financial Results and Highlights Conference
            Call

    When:   Tuesday, May 7, 2013 at 4:30 p.m. ET /1:30
            p.m. PT

    Where: www.isispharm.com

    How:    Live on the Internet.  Simply log onto our Web
            site listed above.

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO(TM), in the United States for the treatment of patients with HoFH. Genzyme is also pursuing marketing approval of KYNAMRO in other markets. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. Regulus Therapeutics(TM) is a trademark of Regulus Therapeutics Inc. KYNAMRO(TM) is a trademark of Genzyme Corporation.

SOURCE Isis Pharmaceuticals Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ISIS PHARMACEUTICALS, INC.
03/23 IONIS PHARMACEUTICALS : Reports from Ionis Pharmaceuticals Highlight Recent Find..
03/17 IONIS PHARMACEUTICALS : ` Latest Attempt To Weaponize Antisense Against Cancer
03/16 IONIS PHARMACEUTICALS : Reports from Ionis Pharmaceuticals Advance Knowledge in ..
03/08 Goldberg Law PC Announces an Investigation of Ionis Pharmaceuticals Inc. and ..
03/06 Levi & Korsinsky, LLP Announces the Commencement of an Investigation of Ionis..
03/06 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ionis Pharmaceu..
03/06 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharma..
03/06 IONIS PHARMACEUTICALS : Akcea and Ionis Announce Positive Results from Pivotal S..
03/01 IONIS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
02/28 IONIS PHARMACEUTICALS, INC. (NASDAQ : IONS) Files An 8-K Results of Operations a..
More news
Sector news : Biotechnology & Medical Research - NEC
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..